(Q40526842)

21 September 2017

1 reference

title

Empiric therapy for infections in the febrile, neutropenic, compromised host (English)

1 reference

21 September 2017

Giamarellou H

1

1 reference

21 September 2017

publication date

1 May 1995

1 reference

Medical Clinics of North America

21 September 2017

published in

1 reference

21 September 2017

volume

79

1 reference

21 September 2017

issue

3

1 reference

21 September 2017

page(s)

559-580

1 reference

A prospective, randomized comparison of ceftazidime and ciprofloxacin as initial empiric therapy in neutropenic patients with fever

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Fungal infections in cancer patients: an international autopsy survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Beta-lactam regimens for the febrile neutropenic patient

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Neutropenia, fever, and infection

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Imipenem versus gentamicin combined with either cefuroxime or cephalothin as initial therapy for febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. The International Antimicrobial Therapy Project Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of t

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Pseudomonas aeruginosa bacteremia in immunocompromised children: analysis of factors associated with a poor outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Empiric amphotericin B therapy in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

A randomized trial of ciprofloxacin plus azlocillin versus netilmicin plus azlocillin for the empirical treatment of fever in neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Aztreonam therapy in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin in the treatment of febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

A comparative study of intravenous ciprofloxacin and benzylpenicillin versus netilmicin and piperacillin for the empirical treatment of fever in neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Empirical antibiotic therapy in neutropenic cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Role of serial microbiologic surveillance and clinical evaluation in the management of cancer patients with fever and granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

A randomized prospective study of ceftazidime and ciprofloxacin with or without teicoplanin as an empiric antibiotic regimen for febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Symposium on infectious complications of neoplastic disease (Part I). Introduction and epidemiology.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of C

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Randomized multicentre study of ciprofloxacin and azlocillin versus gentamicin and azlocillin in the treatment of febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Approaching the controversies in antibacterial management of cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Intravenous ciprofloxacin for infections in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Fungal and bacterial infections in the immunocompromised host

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Controversies in the management of febrile neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Ceftazidime Monotherapy for Empiric Treatment of Febrile Neutropenic Patients: A Metaanalysis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

A clinical, microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Hepatic candidiasis in cancer patients: the evolving picture of the syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Evolving risk factors for invasive fungal infections--all neutropenic patients are not the same

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930057-8

7 January 2021

10.1016/S0025-7125(16)30057-8

Identifiers

DOI

0 references

1 reference